Genmab — Februar 2020

[Bulder]

Nu vi snakker om BMS: "Den amerikanske medicinalkoncern Bristol-Myers Squibb, der for nyligt har gennemført det 74 mia. dollar store opkøb af biotekselskabet Celgene, har torsdag aflagt regnskab for fjerde kvartal, hvor indtjeningen overrasker positivt, mens prognoserne for 2020 er lidt til den svage side.
Aktien indikeres dog 3,0 pct. højere i det amerikanske formarked."

[E_L]

article by your local Dara / MM hero...

[E_L]

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad? https://www.mdpi.com/2073-4409/9/2/378

[E_L]

pdf
https://sci-hub.tw/https://www.mdpi.com/2073-4409/9/2/378

[E_L]

part of Special Issue "CD38 and Disease: A Bi-Directional Cross-Talk between Pathology and Physiology" https://www.mdpi.com/journal/cells/special_issues/CD38_CD157

[Bulder]

I don't quite get the point here. Do they recommend a dara-break or not?

[E_L]

i think they recomend more research before they can decide that...?

[E_L]

it amazed me before, how much is still unknown about the workings of a drug that sells $3bn a year...

[E_L]

this part has focus on CD38 in Solid Tumors https://www.mdpi.com/2073-4409/9/1/52/htm

[Darvin]

1637 - er det så rødvin igen. Det går altså ikke

[Solsen]

[JKY_VH]

Du har ret Darvin, men på den anden side set så kunne der ske værre ting end at Genmab sætter endnu en kursrekord:-)

[Darvin]

Enig - lad dem bare komme - en efter en, og et par trin tilbage tager vi såmænd
også med

[Sukkeralf]

Tisotumab Vedotin Program Highlights

Tisotumab Vedotin innovaTV 204 Pivotal Trial Data Expected in 2020: Seattle Genetics and Genmab expect to report topline data in the first half of 2020 from the innovaTV 204 pivotal trial of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard-of-care treatment.

[Sukkeralf]

Just a moment...

(www.firstwordpharma.com)

[Sukkeralf]

Så ikke rigtig noget nyt derfra !

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

BCMA- CAR-T. JNJ 4528. https://www.onclive.com/web-exclusives/jnj4528-boasts-high-response-rate-in-relapsedrefractory-myeloma?utm_medium=email&utm_campaign=ONCSS MCL CC eNews NO BANNER 2-6-20 NON-US SEND&utm_content=ONCSS MCL CC eNews NO BANNER 2-6-20 NON-US SEND+CID_b62c0ef5d3c78a81dc8c89fb922e8fc8&utm_source=CM ONCLIVE&utm_term=JNJ-4528 Boasts High Response Rate in RelapsedRefractory Myeloma

[bikube]

Nu får vi da godt nok flyttet ATH deropad.

[Helge_LarsenPI-redaktør]